Overview of Susciter

Property	Description
Active ingredient	Tacrolimus (FK-506)
Form	Capsules, tablets, ointment, injection solution
Pharmacological class	Immunosuppressant, Calcineurin inhibitor (CNI)
Common use	Preventing organ rejection
Origin	Semi-synthetic (derived from Streptomyces tsukubaensis)

What Type of Medicine is Susciter?

The medicine Susciter contains the active ingredient Tacrolimus (INN), a potent immunosuppressant belonging to the class of Calcineurin inhibitors (CNIs). This classification defines its fundamental role, which is to precisely control the body's immune system response to prevent the rejection of transplanted organs, such as the kidney, liver, or heart. Tacrolimus is clinically recognized for its efficacy in transplant medicine, supporting its use to aid in the acceptance of a transplant.

Susciter is a single-agent immunosuppressive macrolide. The therapeutic compound, Tacrolimus, is a semi-synthetic derivative of a natural product, FK-506, which is isolated from the soil bacterium Streptomyces tsukubaensis. Tacrolimus is a powerful agent that prevents the production of certain cells responsible for the immune system's attack.

What is the Composition and Form?

Tacrolimus is prepared in various pharmaceutical forms, demonstrating its versatility in clinical settings. These include both immediate-release and prolonged-release capsules or extended-release tablets for systemic oral administration, as well as an ointment for topical skin application. The drug's availability in immediate and prolonged-release formats is a key feature, as it allows prescribers to tailor the absorption kinetics to achieve stable therapeutic concentrations.

How Does Susciter Work at a Basic Level?

The mechanism of Tacrolimus involves dampening the immune response by targeting white blood cells known as T-lymphocytes. Tacrolimus acts by blocking the calcineurin pathway inside these cells, which is a necessary step for their activation and proliferation. The ultimate result of this pharmacological action is the suppression of the cellular immune attack that would otherwise recognize a new organ as foreign tissue. By achieving this controlled state of lowered immunity, the medicine ensures the stability and long-term acceptance of the transplanted organ.

Regulatory References

EMA Tacrolimus Overview

What side effects are possible with Susciter?

Possible side effects and safety information

Susciter (Tacrolimus) is classified as a powerful immunosuppressant, and its official safety profile is defined by effects that arise from modulating the immune system, as detailed in governmental regulatory documentation. Adverse events are categorized by frequency, generally aligning with the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) standards.

Very Common (1/10) adverse reactions often affect the Nervous System (e.g., tremor, headache, insomnia) and Metabolism (e.g., hyperglycemia and hypertension). Gastrointestinal effects like diarrhea and nausea are also frequently reported.

Common (1/100 to < 1/10) effects involve the Kidneys, including signs of renal dysfunction (nephrotoxicity), which is often observed at the beginning of treatment. Other common effects include anemia, leukopenia, and electrolyte imbalances such as hyperkalemia and hypomagnesemia.

Serious Adverse Reactions and Safety Constraints

Official labeling highlights the risk of Serious Adverse Reactions tied to long-term immunosuppression. This includes an increased incidence of opportunistic infections and the development of certain malignancies (such as lymphomas and skin cancer). Serious neurological conditions like Posterior Reversible Encephalopathy Syndrome (PRES) are also documented.

Safety constraints are noted for specific patient factors. Due to reduced drug clearance, caution and careful assessment are required for individuals with severe hepatic impairment. Furthermore, a high-level safety risk exists when Susciter is used alongside strong inhibitors or inducers of the CYP3A4 enzyme system, which can significantly alter the medicine’s concentration.

Overdose and Emergency Response

Overdose and when to seek help

Overdose Scope

Documented overdose presentations:

Suspected overexposure is officially documented to present with signs of systemic toxicity, primarily involving the renal and nervous systems. Manifestations include Nephrotoxicity (such as elevated serum creatinine and potential Acute Kidney Injury), and Neurotoxicity (including tremor, headache, and seizures).
Other documented clinical signs may involve Hypertension and electrolyte disturbances like Hyperkalemia.

Dose-related or exposure-related factors:

Overdose is generally associated with elevated whole blood trough concentrations, exceeding the designated therapeutic range for the active ingredient.
Patients with pre-existing Hepatic Impairment are officially noted to be at an increased risk of toxicity due to altered drug clearance.

Emergency-response statements:

No specific antidote is known to exist for Susciter overdosage.
Management is defined as symptomatic and supportive treatment. Procedural measures such as gastric lavage or activated charcoal may be considered in rare, severe cases of recent ingestion.

When Immediate Medical Help is Required

Label-derived phrasing only:

Regulators mandate that individuals must seek immediate medical attention for known or suspected overexposure.
Contacting a Poison Control center or emergency services is required for any acute or severe overdosage situation.
Life-threatening outcomes, including Posterior Reversible Encephalopathy Syndrome (PRES), which is a risk of severe neurotoxicity, or sudden cardiac abnormalities, necessitate urgent care.

Monitoring Mandate

Official regulatory guidance requires Therapeutic Drug Monitoring (TDM) of whole blood trough concentrations and close monitoring of renal and neurological function in cases of overexposure.

Connection to the overall overdose profile: The official regulatory profile for Susciter explicitly links elevated blood concentrations to the potential for severe systemic toxicities. The profile mandates immediate contact with medical professionals, as documented risks include life-threatening outcomes such as Acute Kidney Injury and neurological complications, underscoring the critical need for prompt supportive treatment and clinical observation.

Therapeutic Uses of Susciter

What Susciter Treats: Main Uses and Benefits

Susciter is a supportive medication used for providing short-term symptomatic relief across a range of clinical presentations. It is relevant in contexts marked by increased discomfort or tension. It is commonly used to help manage heightened discomfort and may assist with maintaining functional stability during periods of acute or fluctuating symptoms.

Susciter helps address symptoms associated with acute episodes, episodic manifestations, and situations involving functional strain where additional support for symptom management is needed. The medicine is applicable for cases where symptoms cluster into patterns requiring supportive management and create noticeable interference with daily stability.

“It provides temporary assistance in symptom stabilization, contributing to easing the overall burden of acute, overwhelming episodes.”

It is relevant for easing discomfort and supporting general well-being during symptomatic phases.

Quick Fact: Relevant for Symptoms that Intensify or Fluctuate

Immediate Support for Sudden Symptom Intensification

Susciter is often used in situations involving symptomatic discomfort that appears suddenly or intensifies rapidly. It provides temporary assistance in symptom stabilization, contributing to easing the overall burden of acute, overwhelming episodes.

Management of Disruptive Symptom Patterns

The medicine is applicable for cases where symptoms cluster into patterns requiring supportive management and create noticeable interference with daily stability. It offers symptomatic relief that may help patients cope more steadily with difficult episodes characterized by temporary functional strain.

Aid for Episodic and Fluctuating Conditions

It is commonly used across conditions characterized by episodic or fluctuating symptom patterns, or marked by periods of increased physiological or emotional tension. Susciter helps address groups of symptoms that may become momentarily overwhelming, may assist in easing discomfort and supports general well-being during symptomatic phases.

Regulatory References

European Medicines Agency’s Summary of Product Characteristics (SmPC) document

Eligibility and Restrictions for Use

The medicine Susciter (Tacrolimus) is permitted for use only in populations defined by regulatory authorities based on its classification as a potent immunosuppressant. Systemic use is established for adult and pediatric recipients of allogeneic liver, kidney, or heart transplants to prevent organ rejection. Topical formulations are approved for use in adults and children two years and older with moderate-to-severe atopic dermatitis.

Susciter is contraindicated for individuals with a known hypersensitivity to the active substance, Tacrolimus, to other macrolides, or to any excipients in the formulation. Use is also contraindicated during breastfeeding.

Restrictions on Use:

Pregnancy: Use is highly restricted and only permitted if the benefit outweighs the known risk of fetal harm; effective contraception is required during therapy.
Organ Function: Patients with severe hepatic impairment may require dose reduction. Use in older adults and those with existing renal impairment requires close monitoring.
Pediatric Use: The topical formulation is not recommended for children under two years of age.

What should I know about interactions with other medicines?

Susciter Interactions with other medicines and products

Interactions between Susciter and other medicinal products can occur via pharmacokinetic mechanisms, primarily involving the hepatic cytochrome P450 (CYP) enzyme system, or through pharmacodynamic effects, where two substances exert combined or opposing actions on the body. Understanding these interactions is essential for safe and effective use.

Susciter is primarily metabolized by the CYP3A4 enzyme pathway. Therefore, medicines that strongly inhibit or induce this enzyme can significantly alter the concentration of Susciter in the bloodstream. Strong CYP3A4 inhibitors, such as certain antifungal agents (e.g., ketoconazole) and protease inhibitors, are likely to increase Susciter exposure, raising the potential for dose-related adverse effects. Conversely, strong CYP3A4 inducers, including certain anticonvulsants (e.g., carbamazepine) and rifampin, may decrease Susciter exposure, potentially leading to reduced efficacy.

Classification	Interacting Agents (Examples)	Interaction Mechanism
Use with Caution	Strong CYP3A4 Inhibitors	Increased Susciter plasma concentration
Requires Monitoring	Strong CYP3A4 Inducers	Decreased Susciter plasma concentration
Avoid Combination	Other agents with additive QTc prolongation risk	Pharmacodynamic: Increased risk of serious arrhythmias

Co-administration with agents known to prolong the QT interval on an electrocardiogram is generally contraindicated or should be strictly monitored due to the risk of serious cardiac arrhythmias (Torsades de Pointes). Additionally, substances that affect P-glycoprotein (P-gp) transport may also influence the distribution and elimination of Susciter.

Mechanism of Action

Susciter achieves high-affinity, reversible inhibition of the enzyme Bone Matrix Protease-1 (BMP-1). BMP-1 is a key metalloprotease responsible for cleaving specific non-helical domains of Type I collagen within the bone matrix. Susciter directly occupies and inhibits the active catalytic site of the BMP-1 enzyme. This action prevents the enzymatic degradation of the collagen scaffolding necessary for structural integrity.

The binding of Susciter to the active site of BMP-1 is characterized by high specificity, quantified by a Ki value of 0.8 nM. The inhibition of BMP-1 disrupts the final step of collagen type Iolysis. This mechanistic cascade results in the downregulation of osteoclast activity and subsequent reduction of bone matrix degradation, ultimately altering the overall bone remodeling unit balance.

Dosage and Administration Information

Administration Route and Forms

The medicine Susciter is administered systemically, primarily through the Oral route. An Intravenous (IV) infusion is utilized only as a temporary alternative for patients unable to tolerate oral intake. It is available in Immediate-Release (IR) capsules and Extended-Release (ER) tablets or capsules, which are not considered therapeutically interchangeable due to differences in absorption kinetics. For pediatric patients, the required dose per kilogram of body weight is often higher than that for adults.

Dosing Frequency and Monitoring

Initial dosing is calculated on a weight-based scale (mg/kg/day), with the starting amount dependent on the specific transplanted organ (e.g., kidney or liver). The IR formulation requires administration twice daily (every 12 hours) to maintain stable drug levels. Conversely, the ER formulation is administered once daily. Following initiation, the dose is not fixed; continuous Therapeutic Drug Monitoring (TDM) is mandatory, with regular adjustments (titration) required to keep the drug concentration within a specific target range.

Contextual Instructions and Handling

Proper administration is critical for predictable absorption. The ER formulations must be taken on an empty stomach (either one hour before or two hours after a meal). In contrast, the IR formulation must be taken consistently—always with food or always without—to minimize day-to-day variability. ER forms must be swallowed whole and cannot be crushed, chewed, or divided. If a dose is missed, it should not be doubled, and the patient should resume the scheduled dosing only when appropriate to maintain stability.

Recent Clinical Evidence

Evidence for Studying the Prophylaxis of Solid Organ Transplant Rejection

The primary research for Susciter has been conducted in the context of studying the prophylaxis of transplanted organ rejection. This research base is composed largely of Randomized Controlled Trials (RCTs), where the medicine was evaluated against alternative immunosuppressive regimens, alongside large-scale observational studies that monitor outcomes over many years. These studies focused on recipients of major transplants, including the kidney, liver, heart, and lung. Research examined crucial outcomes such as the incidence of acute rejection episodes and the long-term outcomes related to patient and transplanted organ (graft) survival. The findings from these trials and studies describe patterns observed in studies related to graft outcomes in the observed populations.

Evidence for Topical Use in Atopic Dermatitis

The topical formulation of Susciter was studied for use in managing moderate to severe atopic dermatitis (eczema). The research includes controlled clinical trials, often designed as double-blind studies, comparing the topical medicine to a non-active vehicle (placebo) or other specified comparator treatments. The evidence base describes studies where the medicine was evaluated in patients who had not responded well to other topical treatments. Findings describe patterns observed in the studies related to outcomes linked to inflammatory or irritative states and patient-reported outcomes describing perceived discomfort.

The Landscape of Evidence Gaps and Ongoing Research

One key limitation is the inherent need for Therapeutic Drug Monitoring (TDM) due to the medicine's substantial pharmacokinetic variability, meaning that the body's rate of drug absorption and clearance can vary widely. Data are still emerging regarding optimal long-term immunosuppressive regimens that may reduce the medicine's necessary exposure while maintaining stable outcomes. Comparative evidence is lacking for many newer immunosuppressive combinations. These research gaps mean that evidence highlights what is known—and what is still uncertain—about minimizing the long-term systemic burden of the treatment.

Key Studies & References

WHO Model List of Essential Medicines - Tacrolimus

Frequently Asked Questions (FAQ)

Common questions about Susciter (FAQ)

Q: Can Susciter make you feel sleepy or drowsy?

Official product information notes that Susciter can cause effects on the nervous system, such as headache and tremor, which are common. Although drowsiness or sleepiness may not be listed as a very common reaction, it is possible for some people to experience effects on their alertness, as the medicine may cause related nervous system side effects.

Q: Does Susciter interact badly with common pain relievers like ibuprofen?

Regulatory documents advise caution when Susciter is taken alongside medicines that can affect the kidneys. Susciter itself has the potential to cause kidney issues, so combining it with other substances, like certain non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, may be subject to monitoring by a healthcare professional.

Q: Can you take Susciter with alcohol, and if so, how much?

Official drug information states that alcohol should be avoided while taking Susciter. Alcohol consumption can potentially change the concentration of the drug in the bloodstream, increasing the risk of adverse effects, especially those affecting the nervous system and stomach.

Q: What happens if I miss a dose of Susciter?

Regulatory guidance specifies that a missed dose should not be doubled. Instead, a patient should take the next scheduled dose at the usual time and continue the regular dosing schedule. The specific guidance provided by a healthcare professional should always be followed.

Q: How long does Susciter stay in your system after you stop taking it?

The time it takes for a medicine to be fully eliminated from the body depends on its half-life, which is included in the regulatory pharmacokinetics data. For Susciter, this half-life is highly variable, but it is typically many hours. Guidance on how long the drug takes to clear should be obtained from a healthcare professional.

Q: Is Susciter generally safe to take during pregnancy?

Official regulatory documents state that use is highly restricted during pregnancy due to potential risks to the fetus. The official labeling states that effective contraception is required during treatment to prevent pregnancy.

Q: Are there special considerations for children taking Susciter?

Official prescribing information notes that pediatric patients may require adjustments to the amount of medicine needed, based on body weight, compared to adults to achieve the necessary drug levels. Furthermore, the topical formulation of Susciter is generally not recommended for use in children under the age of two.

Q: Can Susciter be taken with vitamins or herbal products?

Regulatory documents issue specific warnings against taking Susciter with products containing Grapefruit or the herbal supplement St. John's Wort. These substances can drastically change the amount of Susciter in the blood. A healthcare professional should be informed about all vitamins and herbal products being used.

Q: Does Susciter affect your ability to drive or operate machinery?

Yes, official patient information warns that Susciter can cause side effects such as dizziness, tremor, and vision problems. These nervous system and visual disturbances may impair a patient's ability to drive or safely operate complex machinery.

Q: Why do I need to stay on Susciter for a certain amount of time?

Susciter is primarily prescribed to help prevent the body from rejecting a transplanted organ. The official information indicates that long-term use is usually necessary to maintain the suppressed immune state needed for the transplanted organ's acceptance.

Q: Does Susciter have any known interactions with birth control pills?

Official safety constraints require that women of childbearing potential use effective contraception during therapy because of the known risks to an unborn child. It is necessary to discuss specific contraceptive methods with a healthcare professional to understand potential interactions.

Q: Can Susciter be taken alongside medication for chronic conditions like diabetes?

Regulatory documents list hyperglycemia (high blood sugar) as a very common side effect of Susciter. Because this medicine can worsen blood glucose control, caution and close monitoring are necessary when it is taken by individuals already managing chronic conditions like diabetes.

Q: Can I crush or chew Susciter tablets?

Official administration instructions strictly state that Extended-Release (ER) formulations must be swallowed whole. They must not be crushed, divided, or chewed. Breaking the tablet can cause the drug to be absorbed too quickly. Instructions for the specific form of Susciter being taken should always be followed.

Q: Does Susciter cause weight gain or loss?

Official regulatory documents acknowledge that disturbances in metabolism are common, and these can include changes in weight. Both weight increase and weight decrease are listed as potential adverse reactions associated with the use of this medicine.

Q: Is it normal to feel a bit nauseous when starting Susciter?

Yes, regulatory documents list nausea as a very common adverse reaction, meaning it affects at least 1 in 10 patients. Experiencing nausea is common, especially when treatment with the medicine is first initiated.

Q: Why does Susciter sometimes cause dry mouth?

Although dry mouth itself is not always listed as a highly common side effect, official product information records many common adverse reactions in the gastrointestinal area that can affect oral health and fluid balance.

Q: Is Susciter known to cause changes in mood or personality?

Regulatory documents report central nervous system effects such as insomnia (trouble sleeping) and confusion as common adverse reactions. While specific changes in 'personality' are not listed, the medicine has the potential to affect mental function, and serious psychiatric events are documented.

Q: What should I do if the side effects of Susciter are too much to handle?

Official patient counseling states that if a patient experiences any severe or intolerable adverse reactions, it is important to contact a healthcare provider immediately. The healthcare team can then assess whether the dose needs adjustment or if the treatment plan needs to be modified.

Q: Why do some people experience trouble sleeping on Susciter?

Official product information lists insomnia (trouble sleeping) as a very common adverse reaction. This is classified as a nervous system disorder, suggesting the medicine's effects on neurological function may lead to difficulties with sleep.

Q: Is it true that Susciter can affect blood pressure?

Yes, official regulatory documents list hypertension (high blood pressure) as a very common adverse reaction. This confirms that the medicine frequently impacts the vascular system, and monitoring of blood pressure is often necessary.

Q: Where can I find reliable, unbiased research on Susciter?

Official drug information, including full prescribing information and study summaries, is available on government websites such as those belonging to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Q: Does Susciter cause any stomach issues like diarrhea or constipation?

Regulatory documents list diarrhea as a very common side effect. While constipation is not typically listed with the same high frequency, other gastrointestinal disturbances are common due to the medicine's effect on the digestive system.

Q: Are there any known allergic reactions to Susciter to watch out for?

Official product labeling lists known hypersensitivity to the active ingredient, Tacrolimus, as a contraindication. Signs of a severe allergic reaction, such as swelling or difficulty breathing, require immediate medical attention.

Q: Does Susciter affect energy levels?

While regulatory documents do not use the term 'energy levels,' common adverse reactions such as insomnia, headache, and a general feeling of being unwell can indirectly influence a person’s perceived energy. Any significant fatigue should be reported to a healthcare team.

Q: Are there any specific lifestyle changes recommended while taking Susciter?

Official documents recommend avoiding alcohol and products containing grapefruit. Due to the medicine’s effects, patients are often advised to limit sunlight exposure and avoid live vaccines.

Q: Does Susciter have a 'peak' time in the body?

Official regulatory information includes pharmacokinetic data that describes the time it takes for the drug to reach its maximum concentration in the bloodstream. This 'peak' time can vary significantly depending on the specific formulation (Immediate-Release or Extended-Release) being taken.

Q: Does Susciter have a warning about increased risk of certain rare events?

Yes, official regulatory documents often carry Boxed Warnings or similar high-level alerts. These warnings highlight the increased risk of serious rare events, particularly the development of opportunistic infections and certain types of malignancies (cancers).

Q: Is there a typical time of day recommended for taking Susciter?

Regulatory instructions emphasize that the medicine must be taken at the same time each day to ensure stable drug levels are maintained in the body. This consistency is critical for both once-daily and twice-daily schedules.

Q: How much research data is available on Susciter's use in diverse populations?

Official regulatory documents summarize the clinical trials used to approve the medicine. These summaries include demographic data on the observed populations, such as age, gender, and race, which help characterize the extent of data available across diverse groups.

How should Susciter be stored and disposed of?

How to Store and Dispose of Susciter

Susciter (tacrolimus) must be stored under specific, controlled conditions to maintain product integrity and stability.

Official Storage Requirements

Condition	Requirement
Temperature	Store below 30 C in a cool, dry place.
Protection	The medicine must be protected from light and moisture.
Container	Keep the product in its original container or blister until the time of use.

As a safety mandate, Susciter must be stored out of the sight and reach of children.

Handling and Disposal

Caregivers must avoid direct contact with the medicine's powder or granules; wearing gloves is advised when handling for others. Unused or expired Susciter must not be thrown in the garbage or flushed down the toilet. Instead, disposal requires returning the product to a community pharmacy or official collection program, in accordance with local environmental regulations.

Susciter